BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 30101703)

  • 1. Phytoconstituents and their Possible Mechanistic Profile for Alzheimer's Disease - A Literature Review.
    Basavan D; Chalichem NSS; Kumar MKS
    Curr Drug Targets; 2019; 20(3):263-291. PubMed ID: 30101703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapy of Alzheimer disease].
    Kovács T
    Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroinflammation in pathogenesis of Alzheimer's disease: Phytochemicals as potential therapeutics.
    Vaiserman A; Koliada A; Lushchak O
    Mech Ageing Dev; 2020 Jul; 189():111259. PubMed ID: 32450086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological modulation of GSAP reduces amyloid-β levels and tau phosphorylation in a mouse model of Alzheimer's disease with plaques and tangles.
    Chu J; Lauretti E; Craige CP; Praticò D
    J Alzheimers Dis; 2014; 41(3):729-37. PubMed ID: 24662099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Key Peptides and Proteins in Alzheimer's Disease.
    Penke B; Bogár F; Paragi G; Gera J; Fülöp L
    Curr Protein Pept Sci; 2019; 20(6):577-599. PubMed ID: 30605056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drugs for Targeted Therapies of Alzheimer's Disease.
    Tam C; Wong JH; Ng TB; Tsui SKW; Zuo T
    Curr Med Chem; 2019; 26(2):335-359. PubMed ID: 29714133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms.
    Dehghani R; Rahmani F; Rezaei N
    Rev Neurosci; 2018 Feb; 29(2):161-182. PubMed ID: 28941357
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent therapeutic strategies targeting beta amyloid and tauopathies in Alzheimer's disease.
    Madav Y; Wairkar S; Prabhakar B
    Brain Res Bull; 2019 Mar; 146():171-184. PubMed ID: 30634016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ebselen ameliorates β-amyloid pathology, tau pathology, and cognitive impairment in triple-transgenic Alzheimer's disease mice.
    Xie Y; Tan Y; Zheng Y; Du X; Liu Q
    J Biol Inorg Chem; 2017 Aug; 22(6):851-865. PubMed ID: 28502066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drug targets for Aβ and tau in Alzheimer's disease: a systematic review.
    West S; Bhugra P
    Br J Clin Pharmacol; 2015 Aug; 80(2):221-34. PubMed ID: 25753046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas.
    den Haan J; Morrema THJ; Verbraak FD; de Boer JF; Scheltens P; Rozemuller AJ; Bergen AAB; Bouwman FH; Hoozemans JJ
    Acta Neuropathol Commun; 2018 Dec; 6(1):147. PubMed ID: 30593285
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau therapeutics for Alzheimer's disease: the promise and the challenges.
    Gold M
    J Mol Neurosci; 2002 Dec; 19(3):331-4. PubMed ID: 12540060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.
    Folwell J; Cowan CM; Ubhi KK; Shiabh H; Newman TA; Shepherd D; Mudher A
    Exp Neurol; 2010 Jun; 223(2):401-9. PubMed ID: 19782075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phytochemicals-based Therapeutics against Alzheimer's Disease: An Update.
    Ayaz M; Nawaz A; Naz F; Ullah F; Sadiq A; Islam ZU
    Curr Top Med Chem; 2022; 22(22):1811-1820. PubMed ID: 36029077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacophore-based models for therapeutic drugs against phosphorylated tau in Alzheimer's disease.
    Pradeepkiran JA; Reddy AP; Reddy PH
    Drug Discov Today; 2019 Feb; 24(2):616-623. PubMed ID: 30453058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fuzhisan Ameliorates the Memory Deficits in Aged SAMP8 Mice via Decreasing Aβ Production and Tau Hyperphosphorylation of the Hippocampus.
    Zhang ZX; Zhao RP; Wang DS; Li YB
    Neurochem Res; 2016 Nov; 41(11):3074-3082. PubMed ID: 27518086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Connecting the Dots: Linking the Biochemical to Morphological Transitions in Alzheimer's Disease.
    Baig AM
    ACS Chem Neurosci; 2019 Jan; 10(1):21-24. PubMed ID: 30160095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuropep-1 ameliorates learning and memory deficits in an Alzheimer's disease mouse model, increases brain-derived neurotrophic factor expression in the brain, and causes reduction of amyloid beta plaques.
    Shin MK; Kim HG; Baek SH; Jung WR; Park DI; Park JS; Jo DG; Kim KL
    Neurobiol Aging; 2014 May; 35(5):990-1001. PubMed ID: 24268884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activated human microglia stimulate neuroblastoma cells to upregulate production of beta amyloid protein and tau: implications for Alzheimer's disease pathogenesis.
    Lee M; McGeer E; McGeer PL
    Neurobiol Aging; 2015 Jan; 36(1):42-52. PubMed ID: 25169677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.